Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus

2005 ◽  
Vol 118 ◽  
pp. 23-28 ◽  
Author(s):  
Steven K. Grinspoon
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Human Immunodeficiency Virus ◽  
Immunodeficiency Virus

scholarly journals Prevalence of metabolic syndrome among human immunodeficiency virus and hepatitis C subjects in Southern Brazil

2015 ◽  
Author(s):  
Maristela Beck ◽  
Helen Cezimbra Cezimbra ◽  
Fabio Pedro Pedro ◽  
Francisco Galarreta ◽  
Luiz Felipe Barin
Keyword(s):  
Metabolic Syndrome ◽  
Human Immunodeficiency Virus ◽  
Hepatitis C ◽  
Southern Brazil ◽  
Immunodeficiency Virus

scholarly journals Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach

2020 ◽  
Vol 222 (6) ◽  
pp. 929-939 ◽  
Author(s):  
Chris deFilippi ◽  
Mabel Toribio ◽  
Lai Ping Wong ◽  
Ruslan Sadreyev ◽  
Ida Grundberg ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Human Immunodeficiency Virus ◽  
Endothelial Function ◽  
Immune Activation ◽  
Atherosclerotic Cardiovascular Disease ◽  
Type I ◽  
Integrin Subunit ◽  
Central Adiposity ◽  
Proteomic Approach ◽  
Immunodeficiency Virus

Abstract Background People with human immunodeficiency virus (PWH) demonstrate increased atherosclerotic cardiovascular disease (ASCVD). Statins are being studied to prevent ASCVD in human immunodeficiency virus (HIV), but little is known regarding the effects of statins on a broad range of inflammatory and cardiovascular proteins in this population. Methods We used a highly specific discovery proteomic approach (Protein Extension Assay), to determine statin effects on over 350 plasma proteins in relevant ASCVD pathways among HIV and non-HIV groups. Responses to pitavastatin calcium were assessed in 89 PWH in the INTREPID trial and 46 non-HIV participants with features of central adiposity and insulin resistance. History of cardiovascular disease was exclusionary for both studies. Results Among participants with HIV, PCOLCE (enzymatic cleavage of type I procollagen) significantly increased after pitavastatin therapy and PLA2G7 (systemic marker of arterial inflammation) decreased. Among participants without HIV, integrin subunit alpha M (integrin adhesive function) and defensin alpha-1 (neutrophil function) increased after pitavastatin therapy and PLA2G7 decreased. At baseline, comparing participants with and without HIV, differentially expressed proteins included proteins involved in platelet and endothelial function and immune activation. Conclusions Pitavastatin affected proteins important to platelet and endothelial function and immune activation, and effects differed to a degree within PWH and participants without HIV.

scholarly journals Baseline 10-Year Cardiovascular Risk Scores Predict Cognitive Function in Older Persons, and Particularly Women, Living With Human Immunodeficiency Virus Infection

2020 ◽  
Author(s):  
Felicia C Chow ◽  
Asya Lyass ◽  
Taylor F Mahoney ◽  
Joseph M Massaro ◽  
Virginia A Triant ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Human Immunodeficiency Virus ◽  
Cardiovascular Risk ◽  
Cognitive Function ◽  
Risk Score ◽  
Risk Scores ◽  
Atherosclerotic Cardiovascular Disease ◽  
Composite Effect ◽  
Immunodeficiency Virus ◽  
Ascvd Risk

Abstract Background Cardiovascular disease (CVD) and associated comorbidities increase the risk of cognitive impairment in persons living with human immunodeficiency virus (PLWH). Given the potential composite effect of multiple cardiovascular risk factors on cognition, we examined the ability of the Atherosclerotic Cardiovascular Disease (ASCVD) risk score and the Framingham Heart Study Global CVD risk score (FRS) to predict future cognitive function in older PLWH. Methods We constructed linear regression models evaluating the association between baseline 10-year cardiovascular risk scores and cognitive function (measured by a summary z-score, the NPZ-4) at a year 4 follow-up visit. Results Among 988 participants (mean age, 52 years; 20% women), mean 10-year ASCVD risk score at entry into the cohort was 6.8% (standard deviation [SD], 7.1%) and FRS was 13.1% (SD, 10.7%). In models adjusted only for cognitive function at entry, the ASCVD risk score significantly predicted year 4 NPZ-4 in the entire cohort and after stratification by sex (for every 1% higher ASCVD risk, year 4 NPZ-4 was lower by 0.84 [SD, 0.28] overall, P = .003; lower by 2.17 [SD, 0.67] in women, P = .001; lower by 0.78 [SD, 0.32] in men, P = .016). A similar relationship was observed between FRS and year 4 NPZ-4. In multivariable models, higher 10-year ASCVD risk and FRS predicted lower NPZ-4 in women. Conclusions Baseline 10-year ASCVD risk and FRS predicted future cognitive function in older PLWH with well-controlled infection. Cardiovascular risk scores may help to identify PLWH, especially women, who are at risk for worse cognition over time.

scholarly journals Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators

2020 ◽  
Vol 222 (Supplement_1) ◽  
pp. S1-S7 ◽  
Author(s):  
Steven K Grinspoon ◽  
Pamela S Douglas ◽  
Udo Hoffmann ◽  
Heather J Ribaudo
Keyword(s):  
Cardiovascular Disease ◽  
Human Immunodeficiency Virus ◽  
Disease Prevention ◽  
Gender Diversity ◽  
Coronary Plaque ◽  
Cardiovascular Disease Prevention ◽  
Population Characteristics ◽  
Vascular Events ◽  
Global Epidemic ◽  
Immunodeficiency Virus

Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible.

Sign in / Sign up

Export Citation Format

Share Document